证券代码：003020 证券简称：立方制药 公告编号：2023-043 合肥立方制药股份有限公司 关于召开 2022 年年度业绩说明会的公告 微信扫一扫以下二维码： 合肥立方制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在 巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年度报告》及《2022 年年度 报告摘要》。为便于广大投资者进一步了解公司 2022 年度经营情况，公司将于 2023 年 4 月 26 日（星期三）召开 2022 年年度业绩说明会，具体安排如下： 一、业绩说明会召开时间和地点 召开时间：2023 年 4 月 26 日（星期三）下午 15:30-17:00。 召开地点：约调研平台。 二、业绩说明会召开方式 本次业绩说明会将采用网络远程的方式进行。 三、公司出席人员 计划出席本次说明会的人员有：公司董事长季俊虬先生，副董事长、总经理 邓晓娟女士，独立董事杨模荣先生，保荐代表人任绍忠先生，副总经理、董事会 秘书夏军先生，财务总监勾绍兵先生（具体参会人员将根据实际情况进行调整）。 敬请广大投资者积极参与。 四、投资者参与方式 本公司及董事会全体成员保证 ...

Share Capital and Equity Structure - The company's total share capital increased from 92,640,000 shares to 120,432,000 shares after a capital reserve transfer of 3 shares for every 10 shares held, resulting in an additional 27,792,000 shares[3][7] - The restricted shares increased from 54,101,850 shares to 71,595,385 shares, with a total increase of 17,493,535 shares due to capital reserve transfers and other factors[3][6] - The company issued 2.035 million restricted shares as part of its 2022 equity incentive plan, increasing the total share capital from 120,432,000 shares to 122,467,000 shares[7] - Tang Zhongxian, a former supervisor, holds 394,680 shares that are locked until February 28, 2023, due to his resignation[4] - Dai Tianhe, appointed as vice president, holds 274,740 shares, with 75% (206,055 shares) locked during his tenure[4] - The largest shareholder, Hefei Lifang Investment Group Co., Ltd., holds 24,024,000 restricted shares, which will be unlocked on December 15, 2023[5] - The equity incentive plan includes 2,035,000 restricted shares, with 814,000 shares to be unlocked on October 19, 2023, and the remaining in subsequent years[5] - The company's registered capital as of December 31, 2022 was RMB 120,432,000.00, with a total share capital of 122,467,000 shares[41] - The company's share capital increased by RMB 29,827,000.00 in 2022, reaching RMB 92,640,000.00[36] Financial Performance - Total revenue for 2022 reached 2,579,340,227.28 yuan, a significant increase from 2,273,254,476.86 yuan in 2021[21] - Operating costs for 2022 amounted to 2,376,803,278.74 yuan, compared to 2,096,710,520.90 yuan in 2021[21] - R&D expenses increased to 73,803,566.10 yuan in 2022 from 65,857,993.22 yuan in 2021[21] - Operating profit for 2022 increased to 240,054,921.89 RMB, up from 192,454,402.58 RMB in 2021[22] - Net profit for 2022 rose to 209,607,566.84 RMB, compared to 172,227,170.61 RMB in 2021[22] - Basic and diluted earnings per share (EPS) for 2022 were 1.74, up from 1.43 in 2021[23] - Total revenue for 2022 reached 921,990,714.66 RMB, an increase from 833,474,534.39 RMB in 2021[27] - R&D expenses for 2022 were 71,006,207.68 RMB, up from 62,863,374.18 RMB in 2021[27] - Total liabilities for 2022 increased to 641,534,824.26 RMB, compared to 370,534,154.24 RMB in 2021[24] - Total equity for 2022 stood at 1,480,221,061.41 RMB, up from 1,303,910,770.75 RMB in 2021[25] - Cash flow from operating activities for 2022 was 126,712,592.89 RMB, down from 150,318,002.40 RMB in 2021[29] - Sales revenue from goods and services in 2022 was 2,484,446,384.96 RMB, up from 2,034,582,976.76 RMB in 2021[28] - Total assets for 2022 increased to 2,121,755,885.67 RMB, compared to 1,674,444,924.99 RMB in 2021[25] - Comprehensive income for 2022 was RMB 209,607,566.84[31] - Owner's equity increased by RMB 176,310,290.66 in 2022[31] - The company's total owner's equity at the end of 2022 was RMB 1,150,508,723.99, an increase of RMB 110,588,041.31 compared to the previous year[36][39] - Comprehensive income for 2022 was RMB 185,410,681.20, a significant increase from RMB 152,897,572.20 in 2021[36][39] - Revenue in 2022 reached 2.579 billion yuan, a year-on-year increase of 13.46%[153] - Net profit attributable to shareholders in 2022 was 209.61 million yuan, a year-on-year increase of 21.70%[153] - Net cash flow from operating activities in 2022 was 200.64 million yuan, a year-on-year increase of 26.42%[153] - Total assets at the end of 2022 were 2.122 billion yuan, a year-on-year increase of 26.71%[153] - The company's total revenue for 2022 was 2.579 billion yuan, a year-on-year increase of 13.46%[172] - Revenue from the pharmaceutical retail sector increased by 35.68% to 129.69 million yuan[172] - The company's pharmaceutical industrial sector generated revenue of 965.52 million yuan, accounting for 37.43% of total revenue[172] - The company's pharmaceutical wholesale and distribution sector revenue increased by 15.74% to 1.475 billion yuan[172] - The company's production volume in the pharmaceutical industry increased by 77.48% to 117.68 million units[169] - The company's inventory in the pharmaceutical industry increased by 496.47% to 41.22 million units[169] - The company's sales volume in the pharmaceutical industry increased by 30.56% to 84.37 million units[169] - The company's R&D expenses increased by 12.06% to 73.80 million yuan[174] - The company's management expenses increased by 31.83% to 59.14 million yuan, mainly due to equity incentive costs[174] - The company's financial expenses decreased by 121.63% to -3.55 million yuan, mainly due to increased interest income and exchange rate changes[174] - R&D investment in 2022 was RMB 76,895,433.08, a 6.01% increase compared to 2021[176] - R&D investment accounted for 2.98% of total revenue in 2022, a slight decrease of 0.21% from 2021[176] - Capitalized R&D investment decreased by 11.58% to RMB 650,400 in 2022[176] - Net cash flow from operating activities increased by 26.42% to RMB 200,638,124.66 in 2022[176] - Net cash flow from investing activities was negative RMB 201,804,837.88, a 5.17% increase in outflow compared to 2021[176] - Cash and cash equivalents decreased by 46.97% to RMB 642,579,832.93 at the end of 2022[179] - Inventory increased by 5.77% to RMB 361,764,867.19, mainly due to increased raw material and centralized procurement product stock[179] - Construction in progress increased by 8.29% to RMB 340,892,548.01, driven by fundraising project construction[179] Asset and Liability Structure - Fixed assets grew to 182,376,394.47 yuan in 2022 from 141,887,846.59 yuan in 2021[20] - Construction in progress surged to 340,892,548.01 yuan in 2022 from 130,349,242.59 yuan in 2021[20] - Total assets increased to 2,121,755,885.67 yuan in 2022 from 1,674,444,924.99 yuan in 2021[20] - Accounts payable rose to 246,935,013.64 yuan in 2022 from 149,252,042.76 yuan in 2021[20] - Contract liabilities increased to 42,615,546.58 yuan in 2022 from 14,690,780.16 yuan in 2021[20] - Long-term equity investments decreased to 14,397,960.96 yuan in 2022 from 20,707,582.59 yuan in 2021[20] - Deferred tax assets grew to 8,938,426.84 yuan in 2022 from 5,859,398.31 yuan in 2021[20] - The company's asset and liability structure remained unchanged after the capital reserve transfer[7] - The top 10 shareholders did not engage in any agreed repurchase transactions during the reporting period[9] - Total owner's equity at the beginning of 2022 was RMB 1,303,910,770.75[31] - Capital reserve decreased by RMB 27,792,000.00 due to capital transfer[33] - Profit distribution to owners (or shareholders) was RMB -64,848,000.00[33] - General risk provision extraction was RMB 0.00[33] - Surplus reserve extraction was RMB 14,913,500.00[33] - Total owner's equity at the end of 2022 was RMB 1,480,221,061.41 (calculated from initial balance and increase)[31] - The company's capital reserve increased by RMB 7,143,950.46 in 2022, reaching RMB 526,163,987.29[36] - Retained earnings grew by RMB 105,649,181.20 in 2022, reaching RMB 485,384,736.70[36] - The company distributed RMB 64,848,000.00 to shareholders in 2022, compared to RMB 46,320,000.00 in 2021[36][39] - The company's surplus reserve increased by RMB 14,913,500.00 in 2022, reaching RMB 46,320,000.00[36] - The company's total assets increased by RMB 130,488,481.66 in 2022, primarily due to increased owner contributions and comprehensive income[36] Dividend Distribution - The company distributed a cash dividend of RMB 7.00 per 10 shares, totaling RMB 64,848,000[4] - The company distributed RMB 64,848,000.00 to shareholders in 2022, compared to RMB 46,320,000.00 in 2021[36][39] Business Operations and Strategy - The company has 5 consolidated subsidiaries, including Cube Pharmaceutical Co., Ltd. and Hefei Dayu Pharmaceutical Co., Ltd[42] - The company uses a 12-month operating cycle as the standard for dividing the liquidity of assets and liabilities[45] - For non-controlling business combinations achieved through multiple transactions, the company determines whether these transactions constitute a "package deal" based on specific criteria[46] - The company's financial statements comply with enterprise accounting standards and accurately reflect its financial status, operating results, and cash flows[47] - In non-controlling business combinations, the company recognizes goodwill if the merger cost exceeds the fair value of the identifiable net assets acquired[48] - If the fair value of assets or liabilities cannot be reasonably determined at the acquisition date, the company uses a provisional value and adjusts it within 12 months if necessary[49] - Transaction costs related to business combinations, such as audit and legal fees, are recognized as expenses in the current period[50] - Subsidiaries acquired through business combinations are included in the consolidated financial statements from the date of control[51] - The company adjusts capital reserves when purchasing minority equity or partially disposing of subsidiary equity without losing control[52] - The company classifies joint arrangements as either joint operations or joint ventures and accounts for them accordingly[53] - The company uses the spot exchange rate on the transaction date for foreign currency transactions, with exceptions for specific scenarios such as capitalizable assets and effective hedges[54] - Interest income is calculated based on the financial asset's carrying amount multiplied by the effective interest rate, with adjustments for credit-impaired assets[55] - Financial assets measured at fair value through other comprehensive income (FVOCI) are managed with a business model aimed at both collecting contractual cash flows and selling the asset[55] - Non-trading equity investments can be irrevocably designated as FVOCI at initial recognition, with gains or losses recognized in other comprehensive income[58] - Financial assets measured at fair value through profit or loss (FVTPL) are recognized at fair value, with gains or losses recorded in profit or loss[58] - The company recognizes the difference between the carrying amount and the consideration received for transferred financial assets in profit or loss[59] - Financial liabilities are derecognized when the obligation is discharged, and any difference between the carrying amount and consideration paid is recognized in profit or loss[60] - The company uses valuation techniques supported by sufficient data to determine the fair value of financial instruments[60] - Expected credit losses for receivables are measured based on the present value of the difference between contractual and expected cash flows[62] - Receivables financing is grouped based on credit risk characteristics, with expected credit losses estimated using historical data and forward-looking information[63] - Inventory is measured at the lower of cost or net realizable value, with net realizable value determined based on estimated selling price minus estimated costs to complete, selling expenses, and related taxes[66][71] - The company uses the perpetual inventory system for inventory management[67] - Contract assets are recognized when the company has a right to consideration for goods transferred to customers, contingent on factors other than time passage[68] - Contract assets and liabilities under the same contract are presented net on the balance sheet[68] - Contract costs include both contract acquisition costs and contract fulfillment costs, recognized as assets if they meet specific criteria[69] - Assets related to contract costs are amortized on the same basis as revenue recognition for the related goods or services[69] - Non-current assets or disposal groups classified as held for sale are measured at the lower of carrying amount or fair value less costs to sell[70][73] - The company classifies assets as held for sale when they meet specific criteria, including being available for immediate sale and having a highly probable sale within one year[72] - Inventory impairment is assessed at the individual item level, but for large quantities of low-value items, impairment is assessed at the category level[71] - Contract asset impairment is measured based on the present value of the difference between contractual cash flows and expected cash flows[68] - The fair value of disposal groups held for sale after the balance sheet date increases, and the previously written-down amount should be recovered and recognized within the scope of non-current assets measured under the No. 42 standard. The recovery amount is allocated proportionally based on the book value of each non-current asset in the disposal group, excluding goodwill, and is recorded in current profits and losses[75] - Long-term equity investments include equity investments in subsidiaries, joint ventures, and associates where the company has control, joint control, or significant influence[76] - For long-term equity investments accounted for using the equity method, if the initial investment cost is greater than the fair value of the identifiable net assets of the investee, the initial investment cost is not adjusted. If it is less, the difference is recognized in current profits and losses and the investment cost is adjusted[79] - When the company disposes of long-term equity investments, the difference between the book value and the actual proceeds is recognized in current profits and losses[81] - If the company loses control of a subsidiary due to partial disposal of equity investments, the remaining equity is accounted for using the equity method, and adjustments are made as if the equity method had been applied from the date of acquisition[82] - The company capitalizes borrowing costs directly attributable to the acquisition or production of qualifying assets, while other borrowing costs are recognized as expenses in the period they are incurred[85] - The company capitalizes borrowing costs when specific conditions are met, including asset expenditure, borrowing costs, and necessary construction or production activities[86] - Borrowing costs are suspended if the construction or production of a capitalizable asset is interrupted abnormally for more than 3 months[86] - The company uses the straight-line method to depreciate right-of-use assets, with depreciation periods based on lease terms or asset remaining useful life[87] - Intangible assets are initially measured at cost, including purchase price, taxes, and other directly attributable expenses[88] - The estimated useful lives of intangible assets are determined based on factors such as product life cycles, technological trends, and market demand[89] - The company reviews the useful lives and amortization methods of finite-lived intangible assets annually, adjusting estimates if necessary[90] - Long-term assets are assessed for impairment if there are indications such as significant market price declines or adverse changes in economic or legal environments[91] - Long-term prepaid expenses are amortized over the benefit period or specified duration, with unamortized balances written off if future benefits are no longer expected[92] - Short-term employee benefits, including wages, bonuses, and social insurance contributions, are recognized as liabilities and expensed or capitalized during the service period[93] - Post-employment benefits are classified as defined contribution plans, with contributions recognized as liabilities and expensed or capitalized during the service period[95] - The company recognizes revenue when control of the goods is transferred to the customer, considering factors such as present payment obligation, legal ownership transfer, and physical possession[104] - Revenue from pharmaceutical wholesale and distribution is recognized upon customer receipt of the goods, provided that the payment is expected to be collected and the related costs can be reliably measured[107] - For pharmaceutical retail, revenue is recognized when the control of the goods is transferred to the customer, with sales typically settled via cash, bank cards, medical insurance cards, or Alipay[107] - The company allocates transaction prices to individual performance obligations based on the relative standalone selling prices of the goods promised in the contract[105] - Variable consideration in contracts is estimated using either the expected value or the most likely amount, ensuring that the total transaction price does not exceed the amount that is highly probable of not being subject to significant reversal[105] - The company accounts for significant financing components in contracts by determining the transaction price as if the customer had paid cash at the time control of the goods was transferred, with any difference amortized over the contract period using the effective interest method[105] - Government grants are classified as either asset-related or income-related, depending on their nature and purpose[107] - The company uses the lease liability method to account for leases, recognizing lease liabilities at the present value of lease payments not yet paid, and includes fixed payments, variable payments based on indices or rates, and expected payments for

Financial Performance - The company's revenue for Q1 2023 reached ¥811,816,818, representing a 29.14% increase compared to ¥628,617,238 in the same period last year[3] - Net profit attributable to shareholders was ¥66,141,680, marking a 40.35% increase from ¥47,126,894 in Q1 2022[3] - The company reported a basic earnings per share of ¥0.54, up 42.11% from ¥0.38 in the same quarter last year[3] - Operating profit for Q1 2023 was ¥77,924,247.11, up from ¥54,916,990.14 in Q1 2022, reflecting a growth of 41.9%[23] - Net profit attributable to the parent company for Q1 2023 was ¥66,141,680.02, compared to ¥47,126,894.93 in Q1 2022, representing a year-on-year increase of 40.4%[23] - Total operating revenue for Q1 2023 reached ¥811,816,818, an increase of 29.1% compared to ¥628,617,238.94 in the same period last year[22] Cash Flow and Investments - The net cash flow from operating activities increased by 54.12% to ¥21,600,909 from ¥14,015,957 in the previous year[3] - The total cash inflow from operating activities for Q1 2023 was ¥634,636,626.42, an increase of 22.3% compared to ¥518,954,386.03 in Q1 2022[24] - Cash outflow from investment activities totaled ¥401,060,831.39, a decrease of 18.4% from ¥491,727,786.23 in Q1 2022[25] - The net cash flow from investment activities was -¥401,062,190.31, compared to -¥491,734,373.18 in the previous year, indicating a reduction in cash outflow[25] - Cash inflow from financing activities was ¥42,452,002.44, with a net cash flow of ¥39,276,135.89, compared to a net outflow of -¥3,094,585.68 in Q1 2022[25] - The ending cash and cash equivalents balance was ¥237,039,230.28, significantly higher than ¥124,832,105.75 at the end of Q1 2022, marking an increase of 89.9%[25] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥2,306,025,264.82, an increase of 8.68% from ¥2,121,755,885.67 at the end of the previous year[3] - Total liabilities at the end of Q1 2023 were ¥753,233,707.58, an increase from ¥641,534,824.26 at the beginning of the year, reflecting a rise of 17.4%[19] - Current assets totaled ¥1,557,043,251.17 at the end of Q1 2023, compared to ¥1,452,547,083.20 at the beginning of the year, marking an increase of 7.2%[18] - Long-term equity investments increased significantly to ¥43,735,288.33 from ¥14,397,960.96, showing a growth of 203.5%[18] - The total equity attributable to the parent company increased to ¥1,552,791,557.24 from ¥1,480,221,061.41, representing a growth of 4.9%[20] Operational Highlights - The company experienced a 45.13% increase in accounts receivable, rising to ¥46,576,730 due to increased sales and credit terms[7] - The company’s operating costs rose by 34.70% to ¥51,519,690, corresponding to the revenue growth in the pharmaceutical sector[8] - The company received government subsidies amounting to ¥843,372.06 during the quarter, which is a decrease compared to previous periods[4] - The company received acceptance for the consistency evaluation of Metformin and Glimepiride tablets, and the registration application for Paliperidone raw materials[13] - The company approved the launch of Venlafaxine sustained-release tablets and Oxycodone sustained-release tablets during the reporting period[13] - The company participated in the national centralized procurement bidding for Nifedipine sustained-release tablets but did not win due to pricing factors[13] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,061[10] - The company’s top ten shareholders include various investment funds and individuals, with the largest shareholder holding 4,131,220 shares[12] Corporate Actions - The company is planning a major asset restructuring involving its wholly-owned subsidiary, Anhui Lifan Pharmaceutical Co., Ltd., to introduce new investors[14] - The company’s board approved the asset sale proposal related to Anhui Lifan Pharmaceutical on March 17, 2023[15] - The company held its first extraordinary general meeting of 2023 on March 31, 2023, to approve the asset sale and capital increase proposals[16] Miscellaneous - The report for Q1 2023 was not audited, indicating that the figures may be subject to change upon final review[26]

Group 1: Product Development and Approval - The company is in the final negotiation stage for a significant growth opportunity related to the acquisition of ophthalmic drugs, with a focus on promoting specific eye drop products like "Jin Zhen" and "Pyridostatin Potassium" [1] - The approval for "Nifedipine Controlled-Release Tablets" has been submitted and is expected to be approved this year after passing the production site inspection in March [1] - The production capacity for "Yiqi Hewei Capsules" is nearly saturated, with a new production line expected to be operational in the second half of the year [1] Group 2: Market Strategy and Sales Growth - The company aims to increase its investment in ophthalmic formulation R&D and plans to establish its own ophthalmic production line [1] - The growth potential for essential drugs in hospitals remains significant, with a target for basic drug distribution in healthcare institutions to reach at least 90% [1] - The sales channels for "Clindamycin Gel" include both hospitals and retail [2] Group 3: Business Focus and Future Planning - The company will continue to focus on its pharmaceutical industrial sector while improving the operational quality of its pharmaceutical commercial segment, primarily within the province [4]

合肥立方制药股份有限公司 投资者关系活动记录表 证券代码：003020 证券简称：立方制药 编号：2021-002 | --- | --- | --- | |-----------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

合肥立方制药股份有限公司 投资者关系活动记录表 证券代码：003020 证券简称：立方制药 编号：2022-001 | --- | --- | --- | --- | |--------------------------|-----------------------------|-------------|---------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 | □分析师会议 | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 华创证券：高岳 | | 张泉 | | 时间 | 2022-1-11 10 ： 30 | | | | | 地点 立方营销大楼五楼会议室 | | | | 上市公司接待 人员姓名 | 生 | | 副董事长、总 ...

Group 1: Product Development and Market Position - The company anticipates that the sustained-release nifedipine tablets may be included in the seventh batch of national centralized procurement, while other products are not yet eligible for centralized procurement [1] - The Yiqi Hewei capsules, developed by Jiangsu Provincial Hospital, saw a year-on-year sales growth of 137.98% in 2020 and maintained a good growth trend in 2021 [1] - The company has developed its own laser perforation equipment for the preparation of permeation pump formulations, in addition to purchasing domestic and imported equipment [1] Group 2: New Product Pipeline - The company has obtained approval for several new products in 2021, including sustained-release tramadol hydrochloride tablets, sustained-release nifedipine tablets, and raw materials for methylphenidate hydrochloride [2] - The company is planning to continue investing in innovative drugs for controlled-release formulations and ophthalmic medications based on its existing product lines [2] - The company has received 13 approvals for ophthalmic products in 2021 and is also initiating new projects based on existing products [2] Group 3: Competitive Advantage - The company is recognized for its industrialization capabilities in complex formulations, currently having four products on the market, including sustained-release nifedipine tablets and sustained-release doxazosin mesylate tablets [2] - There are five products in the registration review stage, including sustained-release venlafaxine tablets [2] - The company aims to strengthen its core competitiveness by further industrializing complex controlled-release formulations and integrating them with narcotic drugs [2]